secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001193125-26-021727
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa shareholders approve 15:1 reverse stock split effective Feb 2, 2026
--------------------------------------------------------------------------

- Approved at Special Meeting: 33.7M for, 27.9M against, 0.1M abstentions; no broker non-votes.
- Board set ratio at 15:1; effective 12:01 a.m. ET on Feb 2, 2026; trading begins on split-adjusted basis same day.
- No fractional shares issued; cash paid in lieu based on Jan 30, 2026 closing price adjusted for split ratio.
- Proportionate adjustments to outstanding equity awards, exercise prices, and Series B Preferred conversion price.
- Par value remains $0.18 per share; CUSIP changes to 04962H704; ticker ATOS unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526021727/0001193125-26-021727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526021727/atos-20260120.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-021727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer